Company-Diagnostics Inc Stock News

Choosing U.S.-listed equities that have the characteristics listed below represents an arguably solid starting point when screening the market for potential value opportunities:

Even with COVID-19 cases rising, the prospects for these stocks remain uncertain.

Co-Diagnostics (NASDAQ:CODX) Inc announced that it has completed the acquisition of Idaho Molecular Inc and Advanced Conception Inc to provide the company with all existing and future assets and intel

Even with COVID-19 cases rising, the prospects for these stocks remain uncertain.

Select Medical Holdings (SEM) acquires the remaining Concentra stake from equity holders for $625.6 million.

With stocks offering dialysis services, including DaVita (DVA), facing several issues, it would be prudent to invest in medical care and services stocks like DGX, AMN and CODX instead for 2022.

Co-Diagnostics Inc (CODX) shares closed today 10.2% higher than it did at the end of yesterday. The stock is currently up 1.2% year-to-date, down 13.2% over the past 12 months, and up 62.0% over the past five years. Today, the Dow Jones Industrial Average rose 1.0%, and the S&P 500 rose 1.4%. Trading Activity Shares traded as high as $10.90 and as low as $8.54 this week.Shares closed 49.9% below its 52-week high and 47.9% above its 52-week low.Trading volume this week was 36.4% lower than the 10-day average and 0.7% higher than the 30-day average.Beta, a measure of the stock’s volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price beats the S&P 500 Index today, lags it on a 1-year basis, and lags it on a 5-year basis The company's share price beats the Dow Jones Industrial Average today, lags it on a 1-year basis, and lags it on a 5-year basis The company share price beats the performance of its peers in the Health Care industry sector today, lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -396.6% The company's stock price performance over the past 12 months lags the peer average by -615.5% The company's price-to-earnings ratio, which relates a company's share price to its earnings per share, is 13.5% higher than the average peer. This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to [email protected]. © 2020 Kwhen Inc.

The molecular testing company is expected to benefit from the rise in cases of the omicron COVID-19 variant.

The molecular testing company is expected to benefit from the rise in cases of the omicron COVID-19 variant.

Co-Diagnostics, Inc. (NASDAQ:CODX) was the recipient of some unusual options trading on Wednesday. Investors bought 7,627 call options on the company. This represents an increase of 478% compared to the typical daily volume of 1,319 call options. CODX opened at $9.41 on Friday. The stock has a market capitalization of $271.85 million, a P/E ratio []

Co-Diagnostics (NASDAQ:CODX)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Thursday, TipRanks reports. They presently have a $15.00 price objective on the stock. HC Wainwright’s price objective indicates a potential upside of 60.94% from the company’s current price. Several other equities research analysts have also […]

Definitive merger agreements provide the Company with all existing and future assets, future product iterations, and intellectual property rights of the platform, creating a fully integrated product line and streamlining commercialization

Develops products to detect infectious diseases in humans and animals Offers Logix Smart coronavirus detection test in US and globally Amassed balance sheet of $72.4 million What Co-Diagnostics does:

Co-Diagnostics (NASDAQ:CODX) Inc announced that it has signed agreements to acquire Idaho Molecular Inc and Advance Conceptions Inc for the development of its upcoming at-home/point-of-care diagnost